#United States #Philadelphia #Glioblastoma #Myosin Therapeutics #MT-125

Myosin Therapeutics at the 2026 Society for Neuro-Oncology Annual Meeting

Myosin Therapeutics has made a significant announcement regarding its participation at the upcoming 31st Annual Meeting of the Society for Neuro-Oncology (SNO), scheduled to take place from November 12 to 15, 2026, in Philadelphia, Pennsylvania. This pivotal gathering will feature key figures from the medical community, including the company's CEO, Dr. Courtney Miller, and CMO, Dr. Karen Smith, who will explore crucial developments in their ongoing clinical trials.

The primary focus at the conference will be the Phase 1/2 STAR-GBM clinical trial of MT-125, targeting newly diagnosed patients suffering from MGMT unmethylated glioblastoma (GBM). With ongoing evaluations currently being conducted across various Mayo Clinic sites located in Florida, Arizona, and Minnesota, the trial has shown impressive progress, outpacing initial timelines. Dr. Miller expressed enthusiasm about the event, highlighting that it serves as a platform to engage with clinical investigators and potential development partners, ensuring continued success in advancing their promising therapeutic.

MT-125 represents an innovative approach as a first-in-class non-muscle myosin inhibitor designed to target essential mechanical dependencies within cancer cells. This functional targeting disrupts the cancer cells' ability to grow, divide, invade healthy tissue, repair, and survive. Unlike traditional therapies that focus solely on biochemical pathways, MT-125’s approach taps into the fundamental physical mechanics of tumor biology. The FDA has already awarded it both Orphan Drug Designation for malignant gliomas and Fast Track Designation for GBM, underpinning its importance and innovation within the field of oncology.

The STAR-GBM trial is facilitated by the support of the National Cancer Institute (NCI), with the ongoing phase primarily concentrating on dose escalation studies aimed at determining the optimal levels for MT-125 administration. Plans are already underway for the transition into Phase 2 of the trial, set to commence in early 2027. Future expansions of the trial will incorporate additional treatment regimens, particularly focusing on oral maintenance and synergistic combination therapies.

Furthermore, Myosin Therapeutics is laying the groundwork to broaden its oncology pipeline beyond GBM. Preclinical studies have revealed the potential for MT-125 to address other aggressive and treatment-resistant cancers, positioning the drug as a pan-oncology therapeutic. In 2027 alone, the company is poised to initiate clinical development aimed at two new cancers, showcasing their commitment to addressing various oncological needs.

The SNO meeting, themed “Crossing the Translational Divide From Neurons to Novel Therapies,” is renowned as a leading international conference that gathers clinicians, researchers, and industry representatives to exchange knowledge and discuss the latest advancements in brain tumor research. Myosin's engagement at this conference undoubtedly highlights their focus not only on current trials but also on forging strong clinical and strategic partnerships critical for future successes.

In summary, Myosin Therapeutics continues to position itself at the forefront of cancer treatment innovations with its trailblazing clinical trials and expanding pipeline. The SNO 2026 Annual Meeting will be pivotal in solidifying these efforts and enhancing relationships within the neuro-oncology community, potentially revolutionizing treatment approaches for glioblastoma and beyond.